Carl Dambkowski - 11 Dec 2024 Form 4 Insider Report for Apogee Therapeutics, Inc. (APGE)

Signature
/s/ Matthew Batters, as attorney-in-fact for Carl Dambkowski
Issuer symbol
APGE
Transactions as of
11 Dec 2024
Net transactions value
-$179,872
Form type
4
Filing time
13 Dec 2024, 20:01:11 UTC
Previous filing
11 Dec 2024
Next filing
03 Jan 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APGE Common Stock Options Exercise $41,491 +1,815 +0.7% $22.86 262,613 11 Dec 2024 Direct
transaction APGE Common Stock Sale $198,613 -4,085 -1.6% $48.62 258,528 11 Dec 2024 Direct F1
transaction APGE Common Stock Sale $22,750 -455 -0.18% $50.00 258,073 11 Dec 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APGE Stock Option (Right to Buy) Options Exercise $0 -1,815 -1% $0.000000 173,530 11 Dec 2024 Common Stock 1,815 $22.86 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.
F2 This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.